InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
12
Disclosed sells
2
T+90 hit rate
57%
T+90 mean return
-4.7%
Across 14 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by SEIDENBERG BETH C, Director. Director active across 7 companies, notably Vera Therapeutics, Inc.. Cumulatively, 39 disclosures have been logged. Split: 12 buys · 2 sells. Total volume traded: €2.3m. History available since 8 June 2021. The latest transaction was filed on 28 October 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations39 total
60,000 sharesCommon StockSEC:0001962918-25-000062:0
14,798 shares@ US$48.012328.4% of flowClass A Common StockSEC:0001415889-24-025746:0
1,177 shares@ US$42.01191.9% of flowClass A Common StockSEC:0001415889-24-023779:0
7,206 shares0Common StockSEC:0001551306-24-000122:0
3,787,940 sharesCommon StockSEC:0000950170-24-015465:0
38,763 sharesCommon StockSEC:0001104659-23-082736:0
17,162 shares0Common StockSEC:0001628280-23-023606:0
1,398,900 shares0Common StockSEC:0001628280-23-022017:0
57,000 shares0Common StockSEC:0001140361-23-028161:0
5,116 shares0Common StockSEC:0001628280-23-020505:0
8,540,729 sharesCommon StockSEC:0001209191-23-028884:0
2,300 shares@ US$7.23950.7% of flowClass A Common StockSEC:0001209191-23-022150:0
Ideal exit: 25 Dec 2023 (T+270)
23,908 shares@ US$7.24416.9% of flowClass A Common StockSEC:0001209191-23-021609:0
Ideal exit: 23 Dec 2023 (T+270)
1,833 shares@ US$7.24050.5% of flowClass A Common StockSEC:0001209191-23-021386:0
Ideal exit: 19 Dec 2023 (T+270)
74,045 shares@ US$7.115721.4% of flowClass A Common StockSEC:0001209191-23-020280:0
Ideal exit: 12 Dec 2023 (T+270)
32,844 shares@ US$7.12499.4% of flowClass A Common StockSEC:0001209191-23-019611:0
Ideal exit: 10 Dec 2023 (T+270)
48,003 shares@ US$7.155514.0% of flowClass A Common StockSEC:0001209191-23-018409:0
Ideal exit: 5 Dec 2023 (T+270)
1,000 shares@ US$7.2450.3% of flowClass A Common StockSEC:0001209191-23-016702:0
Ideal exit: 28 Nov 2023 (T+270)
100 shares@ US$7.250.0% of flowClass A Common StockSEC:0001209191-23-015418:0
Ideal exit: 26 Nov 2023 (T+270)
200 shares@ US$7.2350.1% of flowClass A Common StockSEC:0001209191-23-013159:0
Ideal exit: 20 Nov 2023 (T+270)
10,072 shares@ US$7.19722.9% of flowClass A Common StockSEC:0001209191-23-009873:0
Ideal exit: 10 Nov 2023 (T+270)
400 shares@ US$7.250.1% of flowClass A Common StockSEC:0001209191-23-008685:0
Ideal exit: 6 Nov 2023 (T+270)
46,163 shares@ US$7.2413.2% of flowClass A Common StockSEC:0001209191-23-008025:0
Ideal exit: 31 Oct 2023 (T+270)
22,999 shares0Common StockSEC:0001628280-22-027105:0
20,500 shares0Common StockSEC:0001140361-22-024158:0
25 of 39 declarations
About SEIDENBERG BETH C
Beth C. Seidenberg is a Board Member at Vera Therapeutics, Inc., Atara Biotherapeutics, Inc., and Progyny, Inc. She brings valuable experience in governance and strategic development. Her role on these boards is to oversee growth and innovation initiatives, ensuring that the companies achieve their long-term goals.
